Caribou Biosciences (CRBU)

• Market cap: $185M
• 1 day: -11.95%
• 5 days: -1.49%
• 1 month: -16.39%
• 3 months: 2.05%
• 6 months: 154.22%
• Year to date: 18.45%
• 1 year: -9.55%
• 5 years: -87.81%
• 10 years: -87.81%
• Sector: Healthcare
• Industry: Biotechnology

About: Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.

Employees: 147